RG-3421

RG-3421 is a small molecule drug that was initially developed by Roche. It has been investigated primarily for immune system diseases and skin disorders, with its main clinical development focused on the treatment of moderate to severe chronic plaque psoriasis. The drug was evaluated in a randomized, placebo-controlled Phase 2 clinical trial to assess its safety, efficacy, and pharmacokinetics in patients with this condition. The route of administration studied was oral dosing. As of the latest available information (April 2025), the global highest R&D status for RG-3421 is listed as "Pending," indicating it has not reached regulatory approval or widespread clinical use[1][3].